Introduction Studies have shown high prevalence of human immunodeficiency virus (HIV)/sexually transmitted infections (STIs) among men who have sex with men (MSM) globally. Other studies have shown that barriers to accessing the HIV/STI services from the health facilities are among the factors...
Introduction: HIV-1 and HIV-2 are globally known human immunodeficiency virus (HIV) types with 55% genetic difference. Partly dominated HIV-2 type is shown to spread to other countries due to immigration and socio-economic interactions. This study aimed to determine seroprevalence of HIV-1,...
19 September 2025 in European Journal of Preventive Medicine
Background: Time-series models forecasting plays key role in predicting TB cases. Despite of its importance some models consist of limitation that decrease its efficiency. To overcome this, adoption of optimal model with highly proficient forecasting is encouraged. Objective This study was aimed to adopt an optimal Time Series model for forecasting new and relapse Tuberculosis cases in Tanzania. Setting: The study use ARIMA, HWES and LSTM Time series models to find optimal modal that works efficiently on forecasting of TB cases. Methods: A cross-sectional study was conducted at Kibong’oto National Infectious Diseases Hospital, Moshi Tanzania from January 2021 to December 2024. Muilt- stage sampling was used to recruit 3911 TB cases registered from January 2015 to December 2020. A Microsoft Excel 2019 was used to create database with total of 2 columns and 72 row. Dataset was divided into training and testing cutoff points of 69% and 31% respectively to obtain optimal time series models as per Xu & Goodacre (2018). Tables and figures were used for interpretation of results. Results: A total of 3911 TB cases with annual average of 651.83. The periodic variations and declines were observed. The error metric values MAE, MAPE, and RMSE show ARIMA modal better performance on forecasting the TB cases due highest scores than others modals. Conclusion: The ARIMA model offers advanced predictions of TB cases, that help timely planning of prevention and control measures.
30 July 2025 in European Journal of Preventive Medicine
Background: HIV-1 and HIV-2 have globally known HIV types with 55% genetic differences that resulted in the difference in ART treatment outcomes. HIV-1 is worldwide spread compared to HIV-2 dominated partly in Europe, the USA, and west Africa. Current studies have shown the spread of HIV-2 to other countries due to immigration and social economic activities interactions Objective, This study was aimed to determine the Seroprevalence of HIV-1, HIV-2, and HIV1+2 dual infection among the HIV patient on HIV -1 ART regimen treatment in Njombe and Dares salaam, Tanzania. Methods: A retrospective cross-sectional study was conducted from January 2020 to December 2021 at eight HIV Care and Treatment Centers. A total of 300 participants who were on HIV -1 ART regimen treatments from 2017 to 2019 were randomly selected and re-tested to determine HIV types SPSS version 26.0 was used for analysis whereby Percentages, Odds ratios (OR), 95% confidence intervals (CIs), and p-values of ≤0.001 were used for interpretation. Ethical clearance was sought from KNCHRE. All participants were provided with informed consent. Results: The mean age was 35.0 (SD ± 0.24) years. There was more female with HIV-1 110 (53.1%) compared to HIV-2 25 (56.8%) and dual infection. The general prevalence of HIV-1 was 69%, HIV- 2 was 15% and HIV-1+2 dual infections were 16%. In stratification by region, HIV-1 prevalence was high in Dares salaam 108(72%) compared to Njombe 99(66%) p=0.26 while the prevalence of HIV-2 was higher in Njombe 25(17%) compared to Dares Salaam 19(13%) p=0.33 and HIV 1+2 dual infection prevalence was high in Njombe 26(17%) compared in Dares -Salaam 23(15%) p=0.64. Conclusion: The study confirmed the presence of high prevalence of the HIV-2 and HIV 1+2 infections which were previously not found in Tanzania. Therefore, the urgent intervention on initiation of HIV-2 and HIV 1+2 dual infections ART regimen in Tanzania should be in place to reduce risks of poor clinical treatment outcomes of PLHIV with HIV-2 and HIV 1+2 infections.